O	0	10	Randomized
O	11	18	Placebo
O	19	29	Controlled
O	30	35	Trial
O	36	38	of
O	39	42	Low
O	42	43	-
O	43	47	Dose
B-intervention	48	57	Tamoxifen
O	58	60	to
O	61	68	Prevent
B-condition	69	74	Local
I-condition	75	78	and
I-condition	79	92	Contralateral
I-condition	93	103	Recurrence
I-condition	104	106	in
I-condition	107	113	Breast
I-condition	114	129	Intraepithelial
I-condition	130	139	Neoplasia
O	139	140	.

O	141	150	Tamoxifen
O	151	163	administered
O	164	167	for
O	168	169	5
O	170	175	years
O	176	178	at
O	179	181	20
O	182	184	mg
O	184	185	/
O	185	186	d
O	187	189	is
O	190	199	effective
O	200	202	in
O	203	209	breast
O	210	216	cancer
O	217	226	treatment
O	227	230	and
O	231	241	prevention
O	241	242	,
O	243	246	but
O	247	255	toxicity
O	256	259	has
O	260	267	limited
O	268	271	its
O	272	277	broad
O	278	281	use
O	281	282	.

O	283	292	Biomarker
O	293	299	trials
O	300	306	showed
O	307	311	that
O	312	313	5
O	314	316	mg
O	316	317	/
O	317	318	d
O	319	321	is
O	322	325	not
O	326	334	inferior
O	335	337	to
O	338	340	20
O	341	343	mg
O	343	344	/
O	344	345	d
O	346	348	in
O	349	359	decreasing
O	360	366	breast
O	367	373	cancer
O	374	387	proliferation
O	387	388	.

O	389	391	We
O	392	404	hypothesized
O	405	409	that
O	410	411	a
O	412	417	lower
O	418	422	dose
O	423	428	given
O	429	432	for
O	433	434	a
O	435	442	shorter
O	443	449	period
O	450	455	could
O	456	458	be
O	459	461	as
O	462	471	effective
O	472	474	in
O	475	485	preventing
O	486	496	recurrence
O	497	501	from
O	502	508	breast
O	509	524	intraepithelial
O	525	534	neoplasia
O	535	538	but
O	539	543	have
O	544	545	a
O	546	551	lower
O	552	560	toxicity
O	561	565	than
O	566	569	the
O	570	578	standard
O	579	583	dose
O	583	584	.

O	585	587	We
O	588	597	conducted
O	598	599	a
O	600	611	multicenter
O	612	622	randomized
O	623	628	trial
O	629	631	of
O	632	641	tamoxifen
O	641	642	,
O	643	644	5
O	645	647	mg
O	647	648	/
O	648	649	d
O	650	652	or
B-control	653	660	placebo
O	661	673	administered
O	674	677	for
O	678	679	3
O	680	685	years
O	686	691	after
O	692	699	surgery
O	700	702	in
B-eligibility	703	708	women
I-eligibility	709	713	with
I-eligibility	714	721	hormone
I-eligibility	721	722	-
I-eligibility	722	731	sensitive
I-eligibility	732	734	or
I-eligibility	735	742	unknown
I-eligibility	743	749	breast
I-eligibility	750	765	intraepithelial
I-eligibility	766	775	neoplasia
I-eligibility	775	776	,
I-eligibility	777	786	including
I-eligibility	787	795	atypical
I-eligibility	796	802	ductal
I-eligibility	803	814	hyperplasia
I-eligibility	815	818	and
I-eligibility	819	826	lobular
I-eligibility	827	829	or
I-eligibility	830	836	ductal
I-eligibility	837	846	carcinoma
I-eligibility	847	849	in
I-eligibility	850	854	situ
O	854	855	.

O	856	859	The
O	860	867	primary
O	868	871	end
O	872	877	point
O	878	881	was
O	882	885	the
B-outcome-Measure	886	895	incidence
I-outcome-Measure	896	898	of
I-outcome-Measure	899	907	invasive
I-outcome-Measure	908	914	breast
I-outcome-Measure	915	921	cancer
I-outcome-Measure	922	924	or
I-outcome-Measure	925	931	ductal
I-outcome-Measure	932	941	carcinoma
I-outcome-Measure	942	944	in
I-outcome-Measure	945	949	situ
O	949	950	.

B-total-participants	951	955	Five
I-total-participants	956	963	hundred
O	964	969	women
B-age	970	972	75
I-age	973	978	years
I-age	979	981	of
I-age	982	985	age
I-age	986	988	or
I-age	989	996	younger
O	997	1001	were
O	1002	1010	included
O	1010	1011	.

O	1012	1017	After
O	1018	1019	a
O	1020	1026	median
O	1027	1033	follow
O	1033	1034	-
O	1034	1036	up
O	1037	1039	of
O	1040	1041	5
O	1041	1042	.
O	1042	1043	1
O	1044	1049	years
O	1050	1051	(
O	1051	1064	interquartile
O	1065	1070	range
O	1070	1071	,
O	1072	1073	3
O	1073	1074	.
O	1074	1075	9
O	1075	1076	-
O	1076	1077	6
O	1077	1078	.
O	1078	1079	3
O	1080	1085	years
O	1085	1086	)
O	1086	1087	,
O	1088	1093	there
O	1094	1098	were
B-iv-bin-abs	1099	1101	14
B-outcome	1102	1112	neoplastic
I-outcome	1113	1119	events
O	1120	1124	with
O	1125	1134	tamoxifen
O	1135	1138	and
B-cv-bin-abs	1139	1141	28
O	1142	1146	with
O	1147	1154	placebo
O	1155	1156	(
O	1156	1158	11
O	1158	1159	.
O	1159	1160	6
O	1161	1162	v
O	1163	1165	23
O	1165	1166	.
O	1166	1167	9
O	1168	1171	per
O	1172	1173	1
O	1173	1174	,
O	1174	1177	000
O	1178	1184	person
O	1184	1185	-
O	1185	1190	years
O	1190	1191	;
O	1192	1198	hazard
O	1199	1204	ratio
O	1204	1205	,
O	1206	1207	0
O	1207	1208	.
O	1208	1210	48
O	1210	1211	;
O	1212	1214	95
O	1214	1215	%
O	1216	1218	CI
O	1218	1219	,
O	1220	1221	0
O	1221	1222	.
O	1222	1224	26
O	1225	1227	to
O	1228	1229	0
O	1229	1230	.
O	1230	1232	92
O	1232	1233	;
O	1234	1235	P
O	1236	1237	=
O	1238	1239	.
O	1239	1241	02
O	1241	1242	)
O	1242	1243	,
O	1244	1249	which
O	1250	1258	resulted
O	1259	1261	in
O	1262	1263	a
O	1264	1265	5
O	1265	1266	-
O	1266	1270	year
O	1271	1277	number
O	1278	1284	needed
O	1285	1287	to
O	1288	1293	treat
O	1294	1296	of
O	1297	1299	22
O	1300	1301	(
O	1301	1303	95
O	1303	1304	%
O	1305	1307	CI
O	1307	1308	,
O	1309	1311	20
O	1312	1314	to
O	1315	1317	27
O	1317	1318	)
O	1318	1319	.

O	1320	1329	Tamoxifen
O	1330	1339	decreased
B-outcome	1340	1353	contralateral
I-outcome	1354	1360	breast
I-outcome	1361	1367	events
O	1368	1370	by
B-iv-bin-percent	1371	1373	75
I-iv-bin-percent	1373	1374	%
O	1375	1376	(
B-iv-bin-abs	1376	1381	three
O	1382	1383	v
B-cv-bin-abs	1384	1386	12
O	1387	1393	events
O	1393	1394	;
O	1395	1401	hazard
O	1402	1407	ratio
O	1407	1408	,
O	1409	1410	0
O	1410	1411	.
O	1411	1413	25
O	1413	1414	;
O	1415	1417	95
O	1417	1418	%
O	1419	1421	CI
O	1421	1422	,
O	1423	1424	0
O	1424	1425	.
O	1425	1427	07
O	1428	1430	to
O	1431	1432	0
O	1432	1433	.
O	1433	1435	88
O	1435	1436	;
O	1437	1438	P
O	1439	1440	=
O	1441	1442	.
O	1442	1444	02
O	1444	1445	)
O	1445	1446	.

B-outcome	1447	1454	Patient
I-outcome	1454	1455	-
I-outcome	1455	1463	reported
I-outcome	1464	1472	outcomes
O	1473	1477	were
O	1478	1481	not
O	1482	1491	different
O	1492	1499	between
O	1500	1504	arms
O	1505	1511	except
O	1512	1515	for
O	1516	1517	a
O	1518	1524	slight
O	1525	1533	increase
O	1534	1536	in
O	1537	1546	frequency
O	1547	1549	of
O	1550	1555	daily
O	1556	1559	hot
O	1560	1567	flashes
O	1568	1572	with
O	1573	1582	tamoxifen
O	1583	1584	(
O	1584	1585	P
O	1586	1587	=
O	1588	1589	.
O	1589	1591	02
O	1591	1592	)
O	1592	1593	.

O	1594	1599	There
O	1600	1604	were
B-iv-bin-abs	1605	1607	12
B-outcome	1608	1615	serious
I-outcome	1616	1623	adverse
I-outcome	1624	1630	events
O	1631	1635	with
O	1636	1645	tamoxifen
O	1646	1649	and
B-cv-bin-abs	1650	1652	16
O	1653	1657	with
O	1658	1665	placebo
O	1665	1666	,
O	1667	1676	including
B-iv-bin-abs	1677	1680	one
B-outcome	1681	1685	deep
I-outcome	1686	1690	vein
I-outcome	1691	1701	thrombosis
O	1702	1705	and
B-iv-bin-abs	1706	1709	one
B-outcome	1710	1715	stage
I-outcome	1716	1717	I
I-outcome	1718	1729	endometrial
I-outcome	1730	1736	cancer
O	1737	1741	with
O	1742	1751	tamoxifen
O	1752	1755	and
B-cv-bin-abs	1756	1759	one
B-outcome	1760	1769	pulmonary
I-outcome	1770	1778	embolism
O	1779	1783	with
O	1784	1791	placebo
O	1791	1792	.

O	1793	1802	Tamoxifen
O	1803	1805	at
O	1806	1807	5
O	1808	1810	mg
O	1810	1811	/
O	1811	1812	d
O	1813	1816	for
O	1817	1818	3
O	1819	1824	years
O	1825	1828	can
O	1829	1834	halve
O	1835	1838	the
O	1839	1849	recurrence
O	1850	1852	of
O	1853	1859	breast
O	1860	1875	intraepithelial
O	1876	1885	neoplasia
O	1886	1890	with
O	1891	1892	a
O	1893	1900	limited
O	1901	1909	toxicity
O	1909	1910	,
O	1911	1916	which
O	1917	1925	provides
O	1926	1927	a
O	1928	1931	new
O	1932	1941	treatment
O	1942	1948	option
O	1949	1951	in
O	1952	1957	these
O	1958	1967	disorders
O	1967	1968	.
